Woodline Partners LP Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Woodline Partners LP acquired a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 46,986 shares of the biotechnology company's stock, valued at approximately $5,713,000.

Several other hedge funds and other institutional investors have also made changes to their positions in SRPT. Capital International Investors boosted its stake in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after buying an additional 2,437,855 shares during the period. Norges Bank purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $126,315,000. Farallon Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 11.1% in the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock valued at $348,368,000 after buying an additional 285,100 shares during the period. Vestal Point Capital LP purchased a new position in shares of Sarepta Therapeutics in the 4th quarter valued at about $30,398,000. Finally, Summit Partners Public Asset Management LLC boosted its stake in shares of Sarepta Therapeutics by 174.5% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 379,150 shares of the biotechnology company's stock valued at $46,101,000 after buying an additional 241,032 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Price Performance

SRPT traded up $1.12 during trading on Thursday, reaching $38.35. 886,564 shares of the stock were exchanged, compared to its average volume of 1,795,098. The business's 50 day moving average price is $52.32 and its two-hundred day moving average price is $92.86. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of 30.63 and a beta of 0.85. Sarepta Therapeutics, Inc. has a 1 year low of $34.10 and a 1 year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm's revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.73 earnings per share. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on SRPT shares. Piper Sandler decreased their target price on Sarepta Therapeutics from $110.00 to $70.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Scotiabank decreased their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research note on Thursday, March 20th. Cantor Fitzgerald decreased their target price on Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft decreased their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. Finally, JPMorgan Chase & Co. decreased their target price on Sarepta Therapeutics from $169.00 to $84.00 and set an "overweight" rating for the company in a research note on Tuesday, May 20th. Six investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $122.61.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.